Wegovy vs Mounjaro: Eli Lilly to launch full-dose pen device in India as obesity drug race heats up
The US-based drugmaker announced on Thursday that it has received market authorization from the Central Drugs Standard Control Organisation (CDSCO) to launch the Mounjaro KwikPen, a multi-dose, single-patient-use prefilled pen designed for once-weekly administration. Until now, the drug was only available in injectable vials, in two dosage strengths.
The full dosage range will soon be available in India, the company said.
'With this approval, all six dosage options for Mounjaro (tirzepatide) will soon be available in India, supporting a more personalized approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals,' Winselow Tucker, president and general manager, Lilly India, said in the release.
A pen-device is much easier for self-administration and preferred by patients over vials, according healthcare providers.
While Eli Lilly gained an early mover advantage with Mounjaro's March 2025 launch, Novo Nordisk is counting on its pen-device format and insulin market leadership to help it close the gap, its India head Vikrant Shrotriya told Mint earlier this week.
Eli Lilly's Mounjaro has sold over 81,570 units in India, with cumulative sales of ₹ 23.94 crore by May 2025, according to pharma intelligence platform Pharmarack.
Novo Nordisk, which launched its rival drug Wegovy in India this week, has been losing global market share to Lilly in the anti-obesity space and entered the Indian market later.
Both drugmakers face a narrow window to tap into India's largely unmet demand for chronic weight-loss medication—before generics arrive.
Novo Nordisk is expected to lose patent protection on semaglutide, the active compound in Wegovy, by March 2026. Leading Indian pharmaceutical companies including Dr Reddy's, Sun Pharma, Zydus Lifesciences, and Cipla are reportedly preparing to launch lower-cost versions.
Mounjaro is currently priced at ₹ 14,000 monthly for a 2.5 mg vial and ₹ 17,500 monthly for the 5 mg version. The company has not yet disclosed pricing for the remaining dosage options.
Wegovy, also a once-weekly injectable, is being introduced in five dose levels: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The first three are priced at ₹ 4,336 per dose or ₹ 17,345 monthly, while the 1.7 mg dose is priced at ₹ 24,280 and the 2.4 mg at ₹ 26,015 per month.
The growing competition between Lilly and Novo underscores the scale of the opportunity: India is home to more than 254 million people living with obesity and over 100 million adults with diabetes. The Indian weight loss market was estimated to be $25 billion in 2024, and could double in size by 2033, according to Nuvama research.
With lifestyle-related illnesses rising and awareness around medical weight management slowly increasing, both companies are racing to establish a strong foothold before prices crash and the market fragments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
44 minutes ago
- News18
Fit Or Just Fancy? The Blood Test Craze At Bengaluru Gyms
Bengaluru isn't just lifting weights anymore, it's decoding them. Welcome to the city's new fitness obsession: personal biometrics. At a gym in Indiranagar, Bengaluru, 34-year-old techie Karan Mehta wraps up his deadlifts and heads straight into a consultation booth. Not for a physio or dietitian – but for his quarterly blood check. Vitamin D, testosterone, lipid profile, cortisol – the full works. Across the city, in coworking spaces like HSR's health-focused hub or Koramangala's start up dens, it's not uncommon to overhear conversations about gut flora, sleep quality scores, or even ferritin levels. Bengaluru isn't just lifting weights anymore, it's decoding them. Welcome to the city's new fitness obsession: personal biometrics. From Reps to Reports: What's Driving the Blood Test Boom In a city that thrives on optimization of code, commute, and caffeine, health was the next logical target. But this isn't the regular annual check-up. These are diagnostics layered into lifestyle, with monthly or even fortnightly panels built into gym memberships and fitness programs. According to Redseer's 2024 wellness trends report, Bengaluru saw a 53% year-on-year rise in demand for personalized health assessments and diagnostics as part of fitness regimens the highest among Indian metros. The boom is driven by: What Kind of Tests Are People Getting? Not just sugar, thyroid, or cholesterol anymore. Here's what's trending in Bengaluru's fit circles: Full-Body Blood Panels For tracking inflammation (CRP), B12, iron, testosterone, estrogen, thyroid function, and more – especially among those doing weight training or following restrictive diets. Vitamin and Mineral Profiling To justify supplement stacks. Magnesium, D3, zinc, selenium – people want numbers before popping pills. Gut Microbiome Testing Yes, stool samples. To decode digestion, bloating, mental fog, and immunity linked to gut health. Cortisol & Stress Hormone Panels To understand fatigue, weight plateaus, or burnout. Many suspect 'adrenal fatigue" from lifestyle overload. Sleep Data Integration Through wearables like Whoop, Oura Ring, or Fitbit Premium combined with melatonin bloodwork. DNA-Based Fitness and Nutrition Reports Expensive, yes but some health studios now pitch DNA swab tests to personalize workouts and diets. Biohacking or Buzzword? What's Actually Useful We asked experts to decode what's gold and what's gimmick: Useful (if done right): Basic blood panels + thyroid/Vitamin D/B12: Most Indians are deficient and don't know it. Catching these can improve energy, mood, and recovery. Cortisol testing: Helpful for those who overtrain or experience chronic fatigue. Iron and ferritin: Especially for menstruating women, runners, and vegetarians. Glucose & HbA1c: Early diabetes detection is critical — even among 'fit" folks. Overkill (for most people): Microbiome tests: Still an evolving science. You'll likely get generic advice. Testosterone obsession: Unless clinically low, minor variations won't impact you dramatically. DNA kits: Interesting, but expensive. Most don't alter day-to-day decisions much yet. Dr. Anjana G, functional medicine specialist at a wellness clinic in JP Nagar, Bengaluru says: 'A blood test doesn't replace intuition. You shouldn't need a cortisol panel to know you're stressed. But yes, for those who are serious about long-term health, these can reveal blind spots." Are Labs Just the New Protein Shake Counter? Many gyms now have 'wellness partners" – tie-ups with diagnostic labs or health brands. What started as optional add-ons have now become upsells: A handsome monthly subscription fee includes fitness tracking and a quarterly health report. Some elite plans come with personal dashboards and health coach calls. Coworking spaces are offering 'wellness hackathons" – with prizes for best improvements in biomarkers. How This Affects You (Even If You're Not a Gym Rat) If you're the kind who thought walking 10k steps was enough, you're not wrong. But here's where this trend matters: More awareness means early diagnosis. Many folks caught silent thyroid issues or pre-diabetes early. Normalization of regular testing. That's a good public health shift. But also, pressure to be 'always optimizing'. Not everybody is a dashboard. What to Keep in Mind Before You Jump In Before you sign up for the 'Biohacker Platinum Plan", consider: Don't test randomly. Let a certified nutritionist, general physician or sports doc recommend what's needed. Look at trends, not one-off numbers. A single low reading doesn't mean deficiency. Be wary of fear-based upselling. 'You're not absorbing protein!" isn't always true it's a sales line. Data without context can cause anxiety especially if you're new to fitness As Dr. Anjana puts it: 'Just like you wouldn't check your bank balance ten times a day, don't obsess over biomarkers unless you're treating something specific." Bengaluru is Not Just Getting Fitter, It's Getting Quantified The future of fitness in the city isn't just about how you feel, it's about what the blood says, what the wearable tracks, and what the dashboard tells you to tweak. It's smart and futuristic. But it's also a little extra. Know your body and use data wisely. First Published: July 04, 2025, 13:21 IST
Mint
an hour ago
- Mint
Lilly and Novo are the kings of weight-loss drugs. The companies coming for their crowns.
Eli Lilly and Danish pharma giant Novo Nordisk are dominating the market for weight-loss drugs. But a number of competitors are hot on their heels. While Lilly and Novo are still the only two companies with approved weight-loss drugs on sale in the U.S., others are coming for a share of the growing sector. Any way you slice it, the market for weight-loss drugs like the so-called GLP-1 medication made by Lilly and Novo is likely to be huge. Morningstar is one of the most optimistic on this potential, seeing a $200 billion market by 2031. Goldman Sachs cut its estimate in April to $95 billion by 2030, down from $130 billion. That is arguably still a very large number and has attracted more companies to the lucrative industry. Both well-established pharma companies as well as smaller, clinical-stage firms are investing heavily to be able to someday compete with Lilly and Novo. Here's a look at some of the contenders: As one of the largest pharmaceutical companies in the U.S., Amgen has pockets deep enough to invest in the booming obesity drug space, and its drug MariTide has shown potential. Its distinct advantage over current jabs is that it would only have to be injected once a month, as opposed to once a week like Lilly's Zepbound and Novo's Wegovy. In a mid-stage trial, patients lost on average about 20% of their body weight after a year on MariTide, roughly on par with rivals, but a surprisingly large number of participants dropped out due to side effects. A late-stage trial is ongoing. Small cap Viking Therapeutics is a clinical-stage biotech and doesn't yet generate revenue. It announced as late as June 25 that it started a late-stage trial of its injectable weight-loss treatment VK2735. VK2735 is a so-called dual GLP-1 and GIP receptor, meaning it targets two different gut hormones to help control blood sugar levels and appetite, thereby helping patients lose unwanted weight. It's also conducting a mid-stage trial for VK2735 in pill form. An early-stage trial showed adults on the highest dosage of the drug lost on average 8.2% of their body weight in four weeks. This Danish up-and-comer has partnered with Roche and privately held Boehringer Ingelheim to develop next-generation weight-loss drugs. Zealand's portfolio includes medicines targeting both GLPs and GIPs receptors (Dapiglutide/Survodutide/ZP6590) as well as a so-called amylin analog (Petrelintide), which works differently from GLP-1s to increase feelings of fullness. There are hopes that amylin could produce fewer side effects than GLP-1 drugs. Structure Therapeutics is a San Francisco-based clinical-stage biotech that is also developing an amylin receptor agonist, ACCG-2671. It expects to start an early-stage trial of the drug by the end of 2025. Preclinical trials have shown significant weight-loss, but also less severe side effects and muscle mass preservation, according to Structure executives. The company also has an oral GLP-1 candidate in the pipeline. The U.K.'s most valuable company by market capitalization AstraZeneca is another Big Pharma player wanting to get into weight-loss drugs with its candidate AZD5004. The treatment is a small molecule oral GLP-1. Type 2 diabetes patients lost 5.8% of their body weight loss after four weeks of taking the daily pill, with mild to modest gastrointestinal side effects. The drug was licensed by AstraZeneca in 2023 from China's Eccogene and is currently in a mid-stage trial. It has two other injectable weight-loss drugs in the pipeline as well. Swiss-listed Roche is developing three different weight-loss drugs, one in partnership with Zealand Pharma. Its portfolio includes both oral and injectable weight-loss medicines, and both single and dual receptor antagonists. Hopes are high, especially for its oral version, but there have been concerns about side effects. Its jab is in a mid-stage trial while its pill is in an early-stage trial. Write to Elsa Ohlen at
Mint
an hour ago
- Mint
Cities that care: Incorporate caregiving infrastructure into urban planning
Everyone needs care, but the care needs of some are particularly urgent, and this population is steadily rising. The elderly are projected to reach 158 million in 2025 (UNFPA). There are 158 million children under six (UNICEF), and about 40-90 million people with disabilities (World Bank). The care of all these segments requires supportive physical and human infrastructure, as it depends on human skill and care-friendly environments at home and outside. These services can help families secure supplementary care when needed, especially as women continue to be the primary caregivers (Time Use Survey 2025). Similarly, physical infrastructure for care affects how easily primary caregivers can manage their daily responsibilities for their dependents while participating in economic activities. Also Read: Wholesome care: All hospitals should help their patients make living wills Let us choose the latter against the backdrop of childcare and women's increasing participation in the labour force, which rose from 23% in 2018 to 37% in 2023. Since 2019, women's care work has remained over 300 minutes daily, while paid work increased by six minutes. Yet, India's public and workplace infrastructure continues to take 'care" for granted, assuming that the design of public spaces has no impact on it. Unlike roads, railways and power grids designed to facilitate movement and commerce, the care infrastructure, including lactation rooms, changing stations and creches, remain inadequate or completely lacking in modern cities. In metro stations, public parks, courts, police stations, marketplaces and most offices, this infrastructure is either non-existent or inadequate. Navigating streets, buses, railways and footpaths with strollers can be exhausting and impossible, with the hardships compounded for women with disabilities. Despite accessibility features, the National Building Code lacks lactation rooms, rendering public infrastructure inconvenient and exclusionary to breastfeeding mothers returning to work. Without supportive environments, World Health Organization (WHO) guidelines on breastfeeding are difficult to follow for mothers returning to work. As high as 81% of mothers said they were uncomfortable feeding their children in public due to the lack of proper breastfeeding places. Only 6% of Indian mothers feel comfortable breastfeeding in public despite legal protections. Without safe and hygienic spaces, many are forced to skip feedings or use storage closets and public toilets, which are neither safe nor dignified options. An IIT Delhi study found that young mothers with infants are the least mobile in India. These design gaps subtly shape who feels welcome in public spaces and potentially push many women out of the workforce after childbirth, thereby weakening India's economic engine. Also Read: Gender and Age: We need a female perspective on ageing populations India must embed care infrastructure into city planning, workplace design and transportation networks. This requires institutionalizing a future-ready national care policy encompassing three key areas: First, the National Guidelines that mandate lactation centres in health facilities must be extended to all public spaces, with standardized infrastructure like crèches, changing stations, incorporating safe and accessible design. This should be integrated into the National Building Code 2016. Second, investments in human care infrastructure by professionalizing caregiving services and supporting women-led care enterprises. Third, anchor these through a national care policy, linking care to labour, urban development and health, with adequate budgets and workplace protections. These should encourage affordable and high-quality care services from the private sector. Public campaigns normalizing male caregiving roles and reducing stigma around breastfeeding can strengthen care as a pillar of social equity and economic productivity. Globally, countries are reimagining care and its supporting infrastructure. Spain and Colombia are integrating care into city planning. Singapore offers portable lactation pods that can be located and accessed through an app. The US has a legal requirement for lactation rooms, with reasonable lactation breaks for breastfeeding employees. Also Read: India's growth and urban planning: On different planets The UK offers up to £2,000 per child annually to help cover registered childcare expenses. Argentina offers childcare allowances for unemployed or informal workers and childcare in the workplace. Germany offers care insurance to cover the costs of long-term care services. India has the opportunity to craft its unique state-led model rooted in scale, local context and inclusion of families from diverse socio-economic backgrounds. This will allow us to shape a future of work where women are no longer forced to choose between caregiving and economic participation, but are supported in doing both with dignity and freedom. As Nancy Folbre reminds us, 'The work of care is not just an obligation, it is a form of social wealth creation." It is time we designed systems that recognize and reward this critical labour as foundational to a just and thriving economy. The authors are, respectively, associate partner and global lead, gender equality, disability and social inclusion (GEDSI) practice; and senior manager, GEDSI, MicroSave Consulting.
